Accéder au contenu
Merck

Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.

Molecular cell (2020-10-17)
Hon Yan K Yip, Annabel Chee, Ching-Seng Ang, Sung-Young Shin, Lisa M Ooms, Zainab Mohammadi, Wayne A Phillips, Roger J Daly, Timothy J Cole, Roderick T Bronson, Lan K Nguyen, Tony Tiganis, Robin M Hobbs, Catriona A McLean, Christina A Mitchell, Antonella Papa
RÉSUMÉ

The PTEN tumor suppressor controls cell death and survival by regulating functions of various molecular targets. While the role of PTEN lipid-phosphatase activity on PtdIns(3,4,5)P3 and inhibition of PI3K pathway is well characterized, the biological relevance of PTEN protein-phosphatase activity remains undefined. Here, using knockin (KI) mice harboring cancer-associated and functionally relevant missense mutations, we show that although loss of PTEN lipid-phosphatase function cooperates with oncogenic PI3K to promote rapid mammary tumorigenesis, the additional loss of PTEN protein-phosphatase activity triggered an extensive cell death response evident in early and advanced mammary tumors. Omics and drug-targeting studies revealed that PI3Ks act to reduce glucocorticoid receptor (GR) levels, which are rescued by loss of PTEN protein-phosphatase activity to restrain cell survival. Thus, we find that the dual regulation of GR by PI3K and PTEN functions as a rheostat that can be exploited for the treatment of PTEN loss-driven cancers.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Tetraethylammonium borohydride, technical, ≥95% (T)
Sigma-Aldrich
MISSION® esiRNA, targeting human PTEN
Sigma-Aldrich
AS 604850, ≥98% (HPLC), solid
Sigma-Aldrich
AZD6482, ≥98% (HPLC)